Low-Dose Naltrexone FDA Approval History: What Patients and Prescribers Need to Know

The direct answer

Naltrexone is an opioid antagonist that the FDA approved decades ago for opioid use disorder and later for alcohol use disorder, at a standard dose around 50 mg daily. Low-dose naltrexone is the same molecule prescribed at a small fraction of that dose, off-label, for conditions such as fibromyalgia, Crohn's disease, and multiple sclerosis. No FDA new drug application exists for LDN at any dose, and none is required for a physician to prescribe it off-label. Patients access LDN exclusively through 503A compounding pharmacies, which prepare the low-strength capsules or liquid that no commercial manufacturer sells. This is a lawful pathway, but it means LDN's dosing, purity, and quality control depend on the individual compounding pharmacy rather than on FDA premarket review of a finished product.

That distinction, not approval status alone, is what should drive a patient's or prescriber's actual decisions: which condition is being treated, how strong the trial evidence is for that specific condition, and how the compounding pharmacy is vetted.

The FDA history of naltrexone as a molecule

Naltrexone's regulatory story covers two approved uses of the standard-dose drug, plus a long-acting injectable formulation, none of which involve the low-dose range used off-label.

Opioid use disorder

The FDA approved oral naltrexone hydrochloride in the 1980s for blocking the effects of exogenously administered opioids as part of a treatment program for opioid use disorder, at a standard dose in the range of 50 mg daily. Readers who need the exact approval date, original sponsor, and brand name history for citation purposes should confirm these against the current FDA-approved label rather than relying on secondary summaries, since brand ownership and label language have changed over time.

Alcohol use disorder

The label was later expanded to include alcohol use disorder based on clinical trial data supporting reduced relapse and craving at the 50 mg dose. Naltrexone remains one of a small number of FDA-approved oral pharmacotherapies for alcohol use disorder.

Vivitrol: a separate, unrelated formulation

Vivitrol is an extended-release injectable suspension of naltrexone, administered once monthly by intramuscular injection, approved separately from the oral tablet. It is manufactured by Alkermes and is used for alcohol use disorder and opioid dependence in specific clinical contexts. Vivitrol has no connection to compounded low-dose naltrexone; it is a different formulation at a different dose, and confusing the two is a common source of misunderstanding among patients researching LDN.

What "low-dose naltrexone" means, regulatorily

LDN is not a separate drug product. It is naltrexone hydrochloride, the same active ingredient in the approved 50 mg tablet, prepared instead at roughly 1 to 5 mg. No FDA approval exists at this dose range for any condition, and no sponsor has filed a new drug application seeking one.

Why prescribing LDN off-label is legal

U.S. physicians may prescribe an FDA-approved drug at a dose or for an indication not on its label, provided they exercise clinical judgment and inform the patient. This is standard off-label prescribing practice across many areas of medicine. A prescriber writing naltrexone 1.5 mg nightly for fibromyalgia is practicing within this established, legal framework, not operating outside the law. What off-label prescribing does not provide is FDA review of efficacy or safety data at that specific dose and indication; the prescriber and patient are relying on the published literature and clinical judgment instead.

Why compounding is necessary

Commercial manufacturers sell naltrexone only in 50 mg tablets. Splitting a 50 mg tablet down to a 1 to 5 mg dose cannot be done with reliable accuracy at home. This gap is filled by 503A compounding pharmacies, which are licensed to prepare patient-specific formulations under Section 503A of the Federal Food, Drug, and Cosmetic Act, as amended by the Drug Quality and Security Act. The FDA's overview of compounding laws and policies describes the general conditions under which 503A compounding is permitted: a valid patient-specific prescription, a preparation that is not essentially a copy of a commercially available product, compliance with applicable USP compounding standards, and no listing of the active ingredient on FDA's list of drugs withdrawn for safety reasons. Naltrexone at low doses is generally understood to fit this framework because no commercial 1 to 5 mg product exists, but state boards of pharmacy, not FDA, provide most day-to-day oversight of individual compounding pharmacies. Quality control therefore varies pharmacy to pharmacy in a way it does not for an FDA-approved commercial tablet.

What the evidence for off-label use actually looks like

No FDA approval requires trial data at the LDN dose range, so the evidence supporting off-label prescribing comes from a mix of small randomized trials, pilot studies, and observational reports rather than a large, FDA-reviewed program.

Published research most often cited in the LDN literature includes a small pilot crossover study and a somewhat larger follow-up crossover trial in fibromyalgia reporting reduced pain scores on low-dose naltrexone compared with placebo; a small randomized trial in pediatric Crohn's disease reporting a higher clinical response rate on naltrexone than placebo; and a phase II trial in multiple sclerosis that did not show a benefit on MRI lesion volume, though it reported a trend toward improved quality-of-life measures. These studies are frequently referenced by name (commonly attributed to researchers such as Younger and colleagues for fibromyalgia, and Smith and colleagues for pediatric Crohn's disease), but the exact citations, sample sizes, and statistical values found in older secondary summaries should be verified directly against the primary journal articles before being repeated as precise figures. Treat any specific p-value, percentage reduction, or sample size attached to these studies as needing confirmation rather than as established fact until checked against the original publication.

LDN off-label decision framework: what actually changes the calculus

What the naltrexone label says, and what it does not say

The FDA-approved label for standard-dose naltrexone tablets covers opioid use disorder and alcohol use disorder at approximately 50 mg daily, and it carries a boxed warning for hepatotoxicity observed at doses well above the approved dose in controlled trials. The label does not address doses in the 1 to 5 mg range at all, because no sponsor has submitted data at that dose range for FDA review. That silence reflects the limits of what was studied and submitted for approval, not a judgment about safety or efficacy at lower doses.

This is frequently the source of confusion in LDN discussions: patients see a boxed hepatotoxicity warning and assume it applies to their 1.5 mg capsule. The warning was established at doses many times higher than the LDN range, and no confirmed hepatotoxicity signal at doses of 5 mg or below has been established in the published literature reviewed for this article. That said, "no confirmed signal" in a limited evidence base is different from "proven safe," particularly for patients with pre-existing liver disease, which is why baseline liver testing is a reasonable precaution rather than a settled requirement.

Reported side effects at LDN doses

Across the small trials and clinical reports available, LDN's side-effect pattern at 1 to 5 mg differs from the standard 50 mg dose. Sleep disturbance, including vivid dreams and initial insomnia, is the most commonly reported effect and is generally described as resolving within the first few weeks. Mild nausea and headache are also reported, typically early in treatment. Exact percentages for how commonly these occur vary across the small available studies and should not be treated as precise population-level rates; they are best understood as a general pattern rather than a fixed statistic.

Drug interactions and who should not use it without close supervision

The dominant interaction risk applies at any naltrexone dose: co-administration with opioid pain medications or use in a patient who is currently opioid-dependent. Naltrexone will precipitate acute opioid withdrawal in a dependent patient and will block the pain-relieving effect of opioid analgesics. Confirming an opioid-free interval before starting LDN, and communicating LDN use to any other prescriber who might later consider opioid therapy, is a basic safety step regardless of the condition being treated. Patients with significant hepatic impairment, a history of naltrexone hypersensitivity, or acute opioid withdrawal are generally excluded from naltrexone use at any dose based on the standard-dose label's contraindications; whether these same contraindications carry the same weight at 1 to 5 mg has not been separately established and should be discussed with a prescriber rather than assumed.

Why no company has pursued FDA approval for LDN

Naltrexone's patents expired long ago. A sponsor that funded a phase III program large enough to support an LDN new drug application would gain no patent exclusivity, since the molecule is generic; competitors could immediately sell the same doses without having borne the trial costs. That economic disincentive, not a scientific finding against LDN, is the most commonly cited reason no company has pursued approval. The Orphan Drug Act's exclusivity incentive does not currently apply to LDN's largest proposed indications, such as fibromyalgia, because those conditions affect far more than the population threshold the Act sets. Whether a narrower, rarer indication could eventually qualify for orphan status is speculative and not something this article can confirm.

Managing the gap: what documentation and sourcing should look like

Because no major medical society (such as the American College of Rheumatology or the American Academy of Neurology) has issued a formal guideline endorsing LDN, prescribers who offer it typically rely on an individualized, informed-consent-based approach rather than a guideline-driven protocol. The broader ethical framework governing medical practice reflects the principle that physicians may use approved drugs for unapproved purposes when supported by clinical judgment and patient consent, though no guidance specific to LDN exists.

Reasonable documentation for an off-label LDN prescription includes the clinical rationale and evidence reviewed, the patient's understanding that LDN is not FDA-approved for the condition being treated, confirmation of opioid-free status before the first dose, baseline liver testing when hepatic risk factors are present, and the specific compounding pharmacy and formulation strength used. On the pharmacy side, checking for USP-standard compliance for non-sterile compounding, voluntary accreditation (such as PCAB), and a certificate of analysis confirming potency are reasonable steps to reduce the dosing-accuracy risk inherent to compounded products.

What is established, what is plausible, and what is not established

Established: naltrexone at 50 mg is FDA-approved for opioid use disorder and alcohol use disorder. LDN at 1 to 5 mg has no FDA approval for any condition. LDN is obtained through 503A compounding, which is legal but relies on state-level pharmacy oversight rather than FDA premarket review of the finished low-dose product. Naltrexone at any dose will interact with opioids and requires an opioid-free interval before starting.

Plausible but unproven: that LDN's proposed mechanism in conditions like fibromyalgia (modulation of glial cell activity, distinct from classic opioid receptor blockade) explains the symptom improvements reported in small trials. That the standard-dose hepatotoxicity warning has no practical relevance at 1 to 5 mg, based on the absence of reported cases in a still-limited literature.

Not established: that LDN is effective for the range of conditions it is currently prescribed for beyond fibromyalgia and pediatric Crohn's disease, where small trial data exist. That LDN is safe or effective for multiple sclerosis, where the available trial did not meet its primary endpoint. Precise adverse-event rates, exact trial sample sizes, and statistical significance values attributed to specific studies in secondary sources, which should be checked against the original journal articles before being cited as fixed figures.

When to seek care rather than rely on this article

This article does not provide individualized dosing or diagnosis. A patient experiencing signs of liver problems (unusual fatigue, yellowing of the skin or eyes, dark urine, right upper abdominal pain), unexplained opioid withdrawal symptoms, or any severe or worsening symptom after starting LDN should contact the prescribing physician promptly or seek urgent care rather than adjusting the dose independently.